EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Combined ER/PR co-positivity enhances prognostic stratification within molecular subtypes of endometrial cancer

Ruxue Han iD, Yang Chen iD, Shuiqing Xu iD, Tingting Zhang iD, Xingran Jiang iD, Hua Li iD

Journal of Gynecologic Oncology · 2026

DOI: 10.3802/jgo.2026.37.e61 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Ruxue Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Receptors, Progesterone, Receptors, Estrogen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Research Incubation Project, Beijing Chao-Yang Hospital, Capital Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To explore the prognostic value of combined estrogen receptor (ER)/progesterone receptor (PR) expression patterns within molecular subtypes of endometrial cancer (EC), particularly in the prognostically heterogeneous no specific molecular profile (NSMP) subtype. METHODS: A retrospective cohort study of 388 EC patients underwent next-generation sequencing-based molecular classification and ER/PR immunohistochemistry. ER/PR status was categorized as co-positive (coP), co-negative, or discordant. Multivariable Cox models and concordance index (C-index) analyses assessed disease-specific survival (DSS) and progression-free survival (PFS). RESULTS: ER/PR co-positivity independently predicted improved DSS overall (hazard ratio [HR]=0.143; 95% confidence interval [CI]=0.065, 0.314; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsReceptors, ProgesteroneReceptors, EstrogenHumansFemalePrognosisRetrospective StudiesMiddle AgedAgedNeoplasm StagingImmunohistochemistryBiomarkers, TumorAdultAged, 80 and overProgression-Free Survival

Stichwörter der Autor:innen

Endometrial CancerEstrogen ReceptorMolecular ClassificationProgesterone ReceptorPrognosis

Substanzen

Receptors, ProgesteroneReceptors, EstrogenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. hual_gyn@163.com.

ORCID-Profile: Ruxue Han, Yang Chen, Shuiqing Xu, Tingting Zhang, Xingran Jiang, Hua Li

Förderung

  • National Natural Science Foundation of China
  • Clinical Research Incubation Project, Beijing Chao-Yang Hospital, Capital Medical University

Zitieren

APA

Han, R., Chen, Y., Xu, S., Zhang, T., Jiang, X., & Li, H. (2026). Combined ER/PR co-positivity enhances prognostic stratification within molecular subtypes of endometrial cancer. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e61

Vancouver

Han R, Chen Y, Xu S, Zhang T, Jiang X, Li H. Combined ER/PR co-positivity enhances prognostic stratification within molecular subtypes of endometrial cancer. Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e61

BibTeX
@article{Han2026,
  author = {Han, Ruxue and Chen, Yang and Xu, Shuiqing and Zhang, Tingting and Jiang, Xingran and Li, Hua},
  title = {Combined ER/PR co-positivity enhances prognostic stratification within molecular subtypes of endometrial cancer},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  doi = {10.3802/jgo.2026.37.e61}
}
Kostenlos starten →